MicroRNA-3163 targets ADAM-17 and enhances the sensitivity of hepatocellular carcinoma cells to molecular targeted agents

• DOI: 10.1038/s41419-019-2023-1
• Publication Date: 2019-10-14T12:04:23Z
• Authors: Bin Yang; Chunping Wang; Hui Xie; Yiwu Wang; Jiagan Huang; Yihui Rong; Huixin Zhang; Huifang Kong; Yongping Yang; Yinying Lu
• Keywords: Adult; Male; 0301 basic medicine; 0303 health sciences; Carcinoma, Hepatocellular; Liver Neoplasms; Antineoplastic Agents; ADAM17 Protein; Middle Aged; Sorafenib; Article; 3. Good health; MicroRNAs; Young Adult; 03 medical and health sciences; Drug Resistance, Neoplasm; Humans; Female; Molecular Targeted Therapy; Aged

Abstract Molecular targeted agents, such as sorafenib, remain the only choice of an antitumor drug for treatment advanced hepatocellular carcinoma (HCC). The Notch signaling pathway plays central roles in regulating cellular injury/stress response, anti-apoptosis, or epithelial–mesenchymal transition process HCC cells, and is a promising target enhancing sensitivity cells to agents. ADAM metalloprotease domain-17 (ADAM-17) mediates cleavage activation protein. In present study, microRNA-3163 (miR-3163), which binds 3′-untranslated region ADAM-17, was screened using online methods. miRDB pre-miR-3163 sequences were prepared into lentivirus particles infect cells. miR-3163 ADAM-17 inhibited pathway. Infection with enhanced their molecular sorafenib. Therefore, may contribute development more effective strategies HCC.